A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis.
A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications.
Adaptive Biotechnologies Corporation announced today that it has entered into two non-exclusive research collaborations with Pfizer Inc. to support research and development efforts in rheumatoid arthritis and other immune-mediated diseases. The agreements reflect a strategic collaboration focused on applying advanced immune profiling and data-driven discovery approaches to accelerate the development of novel therapies.
Under the terms of the rheumatoid arthritis collaboration, Adaptive is eligible to receive up to $890 million, including upfront payments and potential milestone payments tied to research progress, product development, regulatory achievements, and commercial milestones. Adaptive will lead early-stage discovery and immune analysis activities, while Pfizer will be responsible for later-stage development and global commercialization.
As part of the collaboration, Pfizer will utilize Adaptive’s proprietary technology to analyze immune cells from patients with rheumatoid arthritis to identify disease-relevant T-cell receptors, which play a central role in immune recognition and disease progression. The collaboration is designed to enhance understanding of immune mechanisms underlying rheumatoid arthritis and support the identification of new therapeutic targets.
In addition, Pfizer has entered into a multi-year, non-exclusive data licensing agreement providing access to Adaptive’s internal database that links T-cell receptors with their corresponding antigens. Pfizer intends to use this data to train artificial intelligence models and support drug discovery efforts across multiple immune-related disease areas. Adaptive may receive upfront and recurring annual licensing fees under the data agreement; financial terms were not disclosed.
Adaptive Biotechnologies is a Seattle-based biotechnology company focused on decoding the adaptive immune system through high-throughput sequencing and computational biology to enable the development of diagnostics and therapeutics for cancer, autoimmune diseases, and infectious diseases. Pfizer Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and vaccines to patients worldwide.
By